Cost ranges are approximate market observations as of mid-2026 and vary by brand, city, and clinic
In line with this, by using whole-exome sequencing on diffuse large B-cell lymphoma patients, a loss of the chromosomic region including CT2 gene in half of the patients has been shown
Tirzepatide: Dual GIP and GLP-1 Agonism Tirzepatide is a 39-amino acid acylated peptide with balanced agonism at both the GIP receptor (GIPR) and the GLP-1 receptor
Common side effects (10% or more of patients) Nausea Diarrhea Constipation Vomiting Reduced appetite (intended effect, but may feel uncomfortable initially) Stomach pain or discomfort Indigestion or acid reflux Fatigue Mild injection site reactions Serious side effects (rare but require immediate medical attention) Pancreatitis: severe, persistent abdominal pain that may radiate to the back, often with nausea or vomiting Gallbladder problems: upper right abdominal pain, fever, jaundice, or unusual stool color Severe allergic reactions: rash, swelling of the face or throat, difficulty breathing Kidney issues: often related to dehydration from prolonged vomiting or diarrhea Diabetic retinopathy complications in patients with pre-existing diabetic eye disease Severe hypoglycemia in patients also taking insulin or sulfonylureas Boxed warning: Tirzepatide caused thyroid C-cell tumors in animal studies
